Full video transcriptClick to expand
Auto-generated transcript of @nickolespeps's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Warning, if you pair GHK with MT2 and Retta, you are going to be 10 times hotter.
- 0:05Your ex will text you back and you won't stop looking at yourself in the mirror.
- 0:09And there's nothing you can do about it. You're going to be 10 times confident
- 0:12and you are going to have trip to Turkey's allegations hair transplants because of how fast
- 0:20your hair grows on GHK, as well as those allegations because of how lean you get that fast.
Retatrutide, MT-2, and GHK-Cu: separating signal from TikTok hype
Quick answer
The video promotes a self-administered stack of GHK-Cu (a copper tripeptide with hair follicle and skin signaling research), MT-II (an unapproved synthetic melanocortin agonist), and retatrutide (an investigational triple-receptor GLP-1/GIP/glucagon agonist still in clinical trials), claiming dramatic cosmetic and body composition effects. No peer-reviewed evidence supports synergistic use of these three compounds together, and two of the three (MT-II and retatrutide) carry meaningful safety and regulatory concerns when used outside clinical supervision. Patients interested in any of these agents should consult a licensed telehealth provider before use.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
GHK-Cu (Copper Peptide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide, MT-2, and GHK-Cu: separating signal from TikTok hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GHK-Cu (Copper Peptide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this ghk-cu video claims cluster
Best for searchers checking whether GHK-Cu beauty and recovery claims match the evidence base.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Retatrutide, MT-2, and GHK-Cu: separating signal from TikTok hype" from Nickole. We read the clip as a Peptide social video fact-checks claim about GHK-Cu (Copper Peptide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video promotes a self-administered stack of GHK-Cu (a copper tripeptide with hair follicle and skin signaling research), MT-II (an unapproved synthetic melanocortin agonist), and retatrutide (an investigational triple-receptor GLP-1/GIP/glucagon agonist still in clinical trials), claiming dramatic cosmetic and body composition effects.
The reason this review is not generic is the source wording and the canonical claim label "peptides divinaresearch peptide reta mt2 ghkcu." In this clip, the useful excerpt is: "Warning, if you pair GHK with MT2 and Retta, you are going to be 10 times hotter." That wording changes the review because it points to GHK-Cu (Copper Peptide) safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GHK-Cu (Copper Peptide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video promotes a self-administered stack of GHK-Cu (a copper tripeptide with hair follicle and skin signaling research), MT-II (an unapproved synthetic melanocortin agonist), and retatrutide (an investigational triple-receptor GLP-1/GIP/glucagon agonist still in clinical trials), claiming dramatic cosmetic and body composition effects.
FormBlends verdict
GHK-Cu (Copper Peptide) safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the GHK-Cu (Copper Peptide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes a self-administered stack of GHK-Cu (a copper tripeptide with hair follicle and skin signaling research), MT-II (an unapproved synthetic melanocortin agonist), and retatrutide (an investigational triple-receptor GLP-1/GIP/glucagon agonist still in clinical trials), claiming dramatic cosmetic and body composition effects. No peer-reviewed evidence supports synergistic use of these three compounds together, and two of the three (MT-II and retatrutide) carry meaningful safety and regulatory concerns when used outside clinical supervision. Patients interested in any of these agents should consult a licensed telehealth provider before use.
- Retatrutide is not FDA-approved. Phase 2 data (Jastreboff et al., 2023, NEJM) showed 17.5% average weight loss over 24 weeks in a controlled trial setting, not from self-administered stacks.
- GHK-Cu has demonstrated hair follicle signaling activity in vitro and small human studies, but clinical effect sizes are modest and nothing close to hair transplant-level regrowth has been documented.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- GHK-Cu (Copper Peptide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the GHK-Cu (Copper Peptide) guide, cost path, safety notes, and provider review before acting.
Review GHK-Cu (Copper Peptide)What You'll Learn
- Retatrutide is not FDA-approved. Phase 2 data (Jastreboff et al., 2023, NEJM) showed 17.5% average weight loss over 24 weeks in a controlled trial setting, not from self-administered stacks.
- GHK-Cu has demonstrated hair follicle signaling activity in vitro and small human studies, but clinical effect sizes are modest and nothing close to hair transplant-level regrowth has been documented.
- MT-II is not approved by any regulatory agency for cosmetic or weight loss use and carries documented risks including nausea, flushing, elevated blood pressure, and unintended prolonged erections.
- No peer-reviewed study has examined the combination of GHK-Cu, MT-II, and retatrutide together. Any claimed synergy between the three is speculation, not science.
- Compounded versions of retatrutide are not equivalent to the investigational drug used in clinical trials. Regulatory status varies by jurisdiction and formulation.
- Melanocortin receptor agonists like MT-II do have documented effects on libido and pigmentation, but translating this into a 'confidence' or cosmetic transformation claim goes well beyond what any published research supports.
- Anyone considering peptide therapy should work with a licensed provider who can assess health history, monitor for adverse effects, and prescribe within applicable regulations.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @nickolespeps actually say?
The creator claims that combining GHK-Cu, Melanotan II (MT-II), and retatrutide will make you "10 times hotter," cause rapid hair growth, extreme leanness, and a confidence boost so dramatic your ex will text you back. This is peptide marketing dressed up as personal testimony, and it is worth pulling apart piece by piece.
The stack they are describing involves three very different compounds: GHK-Cu is a copper tripeptide studied for skin and hair follicle signaling; MT-II is a synthetic melanocortin agonist originally investigated for tanning and erectile dysfunction; retatrutide is an investigational triple-receptor agonist (GLP-1, GIP, glucagon) that has shown significant weight loss in early trials. These are not interchangeable or synergistic in any documented, peer-reviewed sense.
Does the science back this up?
Partially, but the framing wildly overstates the evidence. Each compound has legitimate research behind it, but combining them and claiming a multiplicative cosmetic effect is not supported by any published data.
GHK-Cu has shown real signaling activity in hair follicle research. Pickart and Margolina (2018, Cosmetics) reviewed evidence that GHK-Cu stimulates follicle size and activates hair growth genes including VEGF. That is not nothing. But "trip to Turkey allegations" hair growth? No trial has demonstrated that level of effect in humans.
Retatrutide phase 2 data (Jastreboff et al., 2023, New England Journal of Medicine) showed up to 17.5% body weight reduction over 24 weeks, which is clinically meaningful. Calling it extreme leanness is an overstatement of trial conditions, which involved monitored participants, not self-administered peptide stacks.
MT-II does activate melanocortin receptors linked to libido and pigmentation, but its safety profile includes nausea, facial flushing, and spontaneous erections. It is not approved anywhere for cosmetic use.
What did they get wrong (or right)?
They got the general properties of each compound roughly right in spirit, but wrong in degree and framing. GHK-Cu does have hair-related research behind it. Retatrutide does produce significant fat loss in trials. MT-II does affect melanocortin pathways tied to skin tone and libido. Credit where it is due.
What they got wrong is more important. There is no published evidence that stacking these three compounds produces synergistic effects. The "10 times" claim is invented. The confidence boost claim conflates melanocortin receptor activity (which can affect mood and libido) with a personality transformation, which is a stretch that no study supports.
The hair transplant joke implies hair regrowth so fast it looks suspicious. GHK-Cu studies show follicle signaling activity in vitro and in some small human studies, but nothing approaching surgical-level density restoration. Khanna et al. (2015, Journal of Cosmetic Dermatology) found topical GHK-Cu improved hair density in a small sample, but effect sizes were modest.
The framing also ignores real risks. MT-II is unregulated, widely counterfeited, and has a documented side effect profile. Retatrutide is still in trials. Combining them without clinical oversight is not a beauty hack.
What should you actually know?
Each of these compounds is being actively researched, and some of the underlying science is genuinely interesting. That does not make a self-administered three-peptide stack safe, legal in all jurisdictions, or proven to do what this video claims.
Retatrutide is not approved by the FDA. It is available through compounded pharmacies in some contexts, but compounded retatrutide is not the same as the clinical trial formulation, and no regulatory body has approved it for weight loss. MT-II is not approved for any cosmetic indication and carries real cardiovascular and dermatological risks at higher doses.
GHK-Cu is the least controversial of the three and is found in some topical cosmetic products. Even so, injectable GHK-Cu exists in a regulatory gray zone depending on jurisdiction and formulation.
If you are interested in any of these compounds, the right move is a conversation with a licensed provider who can review your health history, not a TikTok stack recommendation. The science here is early. The hype is way ahead of it.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nickole · TikTok creator
105.8K views on this video
@DivinaResearch #peptide #reta #mt2 #ghkcu
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide?
Retatrutide is not FDA-approved. Phase 2 data (Jastreboff et al., 2023, NEJM) showed 17.5% average weight loss over 24 weeks in a controlled trial setting, not from self-administered stacks.
What does the video say about ghk-cu has demonstrated hair follicle signaling activity in vitro?
GHK-Cu has demonstrated hair follicle signaling activity in vitro and small human studies, but clinical effect sizes are modest and nothing close to hair transplant-level regrowth has been documented.
What does the video say about mt-ii?
MT-II is not approved by any regulatory agency for cosmetic or weight loss use and carries documented risks including nausea, flushing, elevated blood pressure, and unintended prolonged erections.
What does the video say about no peer-reviewed study has examined the combination of ghk-cu, mt-ii,?
No peer-reviewed study has examined the combination of GHK-Cu, MT-II, and retatrutide together. Any claimed synergy between the three is speculation, not science.
What does the video say about compounded versions of retatrutide?
Compounded versions of retatrutide are not equivalent to the investigational drug used in clinical trials. Regulatory status varies by jurisdiction and formulation.
What does the video say about melanocortin receptor agonists like mt-ii do have documented effects on?
Melanocortin receptor agonists like MT-II do have documented effects on libido and pigmentation, but translating this into a 'confidence' or cosmetic transformation claim goes well beyond what any published research supports.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Nickole, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.